What Is Octreotate? Definition and What Research Reports

Octreotate is a synthetic cyclic octapeptide — an eight-amino-acid analogue of the natural hormone somatostatin — designed to bind somatostatin receptors, especially subtype 2 (SSTR2). It differs from the better-known analogue octreotide by a single terminal modification: the C-terminal threoninol of octreotide is replaced by the amino acid threonine, which is why the molecule is often written as Tyr³-octreotate or TATE. Octreotate is rarely discussed on its own; in practice it appears as a conjugate in which a chelator (usually DOTA) is attached to the peptide so that a radioactive metal — most commonly lutetium-177 — can be carried to receptor-expressing tissue. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medical imaging.

Where the Molecule Comes From

Somatostatin is a short endogenous regulatory peptide with a very brief circulating half-life. Medicinal chemistry programmes in the twentieth century produced stabilised analogues that retained receptor binding but resisted rapid degradation; octreotide was the first widely used member of that family, and octreotate emerged as a closely related variant with high affinity for SSTR2. Octreotate itself is made by solid-phase peptide synthesis rather than extracted from tissue. Because many neuroendocrine tumours over-express somatostatin receptors, the peptide functions as a targeting vector: the peptide finds the receptor, and whatever is attached to the peptide — a radionuclide, or in laboratory work a fluorophore — goes with it.

How the Term Is Used in the Literature

Readers encountering "octreotate" in a paper title will almost always see it inside a longer construct name. Common forms include:

• [¹⁷⁷Lu]Lu-DOTA⁰-Tyr³-octreotate — the therapeutic radiopharmaceutical used in peptide receptor radionuclide therapy (PRRT), frequently abbreviated ¹⁷⁷Lu-octreotate or ¹⁷⁷Lu-DOTATATE.
• Octreotate scan — shorthand for receptor imaging performed with a radiolabelled octreotate tracer; one report evaluated the role of octreotate scanning in discriminating solitary pulmonary nodules (PMID 25191112).
• Fluorescent octreotate conjugates — non-radioactive laboratory probes; a 5-carboxy-fluorescein-labelled octreotate has been described as a molecular imaging agent entry in the preclinical literature (PMID 20734502).

The distinction between "octreotate" and "octreotide" matters in research writing because the two conjugates are not interchangeable. A preclinical comparison in human neuroblastoma-bearing mice directly evaluated ¹⁷⁷Lu-octreotate against ¹⁷⁷Lu-octreotide for treatment effect (PMID 38826727).

What the Published Literature Reports

Research on octreotate is dominated by nuclear medicine rather than by the bare peptide. Several themes recur.

Preclinical tumour-model work

Animal studies have examined how the delivery schedule and pharmacological context change tumour response. Researchers using a human small-intestine neuroendocrine GOT1 tumour model reported that hyperfractionated administration of ¹⁷⁷Lu-octreotate increased tumour response compared with the comparator schedules studied (PMID 35008397). A separate cell-based study reported that a PARP inhibitor potentiated ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy in human neuroendocrine tumour cells (PMID 29872498). Formulation and measurement work has also been published, including in vivo measurement and characterisation of a novel formulation of [¹⁷⁷Lu]-DOTA-octreotate (PMID 27904871).

Clinical outcome and dosimetry reports

In patients, the published record centres on neuroendocrine tumours. A long-term analysis reported survival and toxicity outcomes in patients with neuroendocrine tumours treated with ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy (PMID 35363879). A single-centre experience examined safety and efficacy of re-treatment with [¹⁷⁷Lu]Lu-DOTA-octreotate in progressive gastro-entero-pancreatic neuroendocrine tumours (PMID 40137978). Because the radiolabelled peptide is cleared through the kidneys, dosimetry is a recurring topic: one report described implementation of patient dosimetry in clinical practice after targeted radiotherapy using [¹⁷⁷Lu-[DOTA⁰, Tyr³]-octreotate (PMID 30498938).

Administration and delivery problems

Two published reports address what happens when the infusion does not reach the bloodstream as intended. One described effective management of ¹⁷⁷Lu-DOTA⁰-Tyr³-octreotate extravasation (PMID 33323730), and another developed infusion modelling for real-time detection and characterisation of extravasation during PRRT (PMID 35503186). These are hospital-procedure papers, not consumer-facing material, and they underline that octreotate in its clinically studied form is a radiopharmaceutical handled under nuclear medicine controls.

Octreotate at a Glance

Tolerability and Organ Effects: What Studies Report

Because the radionuclide, not the peptide alone, drives most observed effects, the safety literature is framed around radiation dose to normal tissue. Renal outcomes have been studied specifically: one investigation examined nephrotoxicity after PRRT with ¹⁷⁷Lu-DOTA-octreotate (PMID 27160225). Longer-term follow-up of treated neuroendocrine tumour patients reported both survival and toxicity endpoints (PMID 35363879), and the re-treatment analysis reported safety alongside efficacy in progressive gastro-entero-pancreatic disease (PMID 40137978). Local tissue exposure from an infusion that leaks outside the vein is the subject of the extravasation case management report (PMID 33323730) and the real-time detection modelling work (PMID 35503186). Patient-specific dosimetry, described as an implementable clinical practice after ¹⁷⁷Lu-octreotate therapy, exists partly to quantify absorbed dose to organs at risk (PMID 30498938).

What Octreotate Is Not

Octreotate is not a general-purpose research peptide in the sense that term is used for growth-factor fragments or metabolic peptides. Its published literature is overwhelmingly oncologic and radiochemical. Statements about octreotate that do not specify the chelator and radionuclide are ambiguous, because the bare peptide, the DOTA conjugate, and the lutetium-177-labelled conjugate have different properties and different bodies of evidence. Approved radiopharmaceutical products containing a DOTA-Tyr³-octreotate construct are administered in licensed nuclear medicine facilities under radiation-safety regulation; this page describes the published literature only and does not describe any protocol or setting of use. Again, this page is educational and is not medical advice.

References

• Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation (Clinical Nuclear Medicine, 2021)
• Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate (European Journal of Nuclear Medicine and Molecular Imaging, 2016)
• 5-Carboxy-fluorescein-labeled octreotate (2004)
• Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience (European Journal of Nuclear Medicine and Molecular Imaging, 2025)
• Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model (Cancers, 2022)
• 177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT (EJNMMI Physics, 2022)
• Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate (EJNMMI Research, 2018)
• Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy (Cancer, 2022)
• The role of octreotate scan in discrimination of solitary pulmonary nodule (World Journal of Nuclear Medicine, 2014)
• Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice (Heliyon, 2024)
• In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate (Asia Oceania Journal of Nuclear Medicine & Biology, 2016)
• Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor (Oncotarget, 2018)